Executive Director of FutureMed, Physician, Scientist, and Entrepreneur
Daniel Kraft, M.D. is an NIH funded faculty member affiliated with Stanford. He was on clinical faculty with the UCSF pediatric bone marrow transplantation service and serves as the medicine track chair for Singularity University where he is also executive director for the FutureMed executive program.
Daniel is the founder of StemCor Systems and founder and consulting chief medical officer for RegenMed Systems, a clinical-stage medical device company that develops tools to enable regenerative stem cell therapies. He is the inventor of the MarrowMiner, a minimally invasive device for the harvest of bone marrow derived stem and progenitor cells. This device is being commercialized by Hospira Inc. for use in bone marrow transplantation and by RegenMed Systems for use in regenerative medicine.
Dr. Kraft received a degree in Biochemistry from Brown University and his M.D. from the Stanford University School of Medicine. He completed the Harvard combined residency in Internal Medicine and Pediatrics at the Massachusetts General Hospital and the Boston Children’s Hospital, before returning to Stanford for clinical fellowship training in hematology/oncology and bone marrow transplantation and a post-doctoral fellowship with Dr. Irving Weissman. Dr. Kraft is board certified in both Pediatrics and Internal Medicine.
In addition to his research and scientific papers, Dr. Kraft has spoken publicly on, performed research into, and consulted on: health data, health statistics, personalized medicine, heath decision making, the future of medicine, and emerging medical technologies.
As part of his early research at the National Institutes of Health, Dr. Kraft conceived of and demonstrated proof of concept for a monoclonal antibody-based therapy for treating allergic disease; his general approach was later translated to an antibody Xolair therapeutic by Genentech. As a Howard Hughes Medical Institute medical student research fellow at Stanford, he discovered at novel population of developing T-cells, which play a role in HIV infection. His research focuses extensively on stem cell biology, immunology, and regenerative medicine.
Dr. Kraft’s research focuses on: stem cell biology and regenerative medicine, stem cell derived immunotherapies for cancer, bioengineering, the hematopoietic stem cell niche in murine and human systems, human T-cell differentiation, and humanized animal models. Dr. Kraft’s clinical work focuses on: bone marrow / hematopoietic Stem cell transplantation for malignant and non-malignant diseases in adults & children, medical devices to enable stem cell based regenerative medicine, including marrow derived stem cell harvesting, processing and delivery.
Dr. Kraft built the first Internet-based alphanumeric paging system at the Stanford hospitals to facilitate communication between clinical staff, and later for elements of Stanford internal medicine and bone marrow transplant service.
In addition to his research at and in connection with Stanford University, Dr. Kraft has performed research into and consulting on health data, health statistics, personalized medicine and heath decision making, including work as an adviser to CollabRx (personalized oncology), Wellsphere (health and wellness) (acquired by HealthCentral), Cepheid (point of care diagnostics), and to the X-Prize Foundation.
To request Daniel Kraft, M.D. to speak at your next event, contact:
Robinson Speakers | The Gold Standard For Keynote Speakers
646-504-9849 | email@example.com